MacroGenics Inc (MGNX) - Profit After Payment of Taxes

MacroGenics, Inc. (MGNX) generates revenue through the commercialization of Margenza therapy and licensing fees for DART technology. Its clients include oncology centers and patients with metastases, with payments guaranteed by government agencies and insurance companies. The company's total profit demonstrates a liquidity inflow, while -0.01 is recorded as the baseline value. Stable royalties from approved products will balance the development portfolio, mitigating the specific risks inherent to the biopharmaceutical sector.

MGNX (MacroGenics, Inc.) Net Profit history from 07/04/2022 to 10/30/2026

Analytical breakdowns and data insights for company MacroGenics (MGNX)

- current quotes and average value forecast:

Market Chart MacroGenics Inc.|MGNX - Consensus Target

- market capitalization indicators:

Market Value MacroGenics Inc.|MGNX - Real Price to Acquire Entire Company

- balance sheet net asset value indicators:

Accounting Value of a Share MacroGenics|MGNX - Book Capitalization|Market Cap to Net Assets Ratio macrogenics.com|MGNX - Company Total Assets

- debt and solvency information:

- net income and valuation multiples indicators:

MGNX - Company Net Income

Fundamental valuation:MGNX, MacroGenics Inc.

Manufactured product of MacroGenics Inc.

This indicator captures the average daily share of net profit, allowing for a real-time assessment of the actual monetization efficiency of MacroGenics, Inc. (MGNX) intellectual property and DART patent barriers under strict FDA oversight. By analyzing the company's profit margins, an investor can identify the gap between accounting growth and actual cash flow, which is critical for confirming the financial stability of MacroGenics, Inc. (MGNX) during prolonged clinical trials.

Direct competitors